REVEALED: Merck co org | Vintage Vibes

Merck & Co. Stock: Is Wall Street Bullish or Bearish?

Merck & Co. has significantly outperformed the broader market, while higher earnings guidance and bullish analyst sentiment support optimism despite declining EPS.

Barchart · Nov 4

Here's What to Expect From Merck & Co.'s Next Earnings Report

Merck & Co. is set to release its third-quarter earnings in a couple of weeks, and analysts are expecting its EPS to grow by a single digit.

Barchart · Oct 13

3 Healthcare Dividend Stocks Offering More Than Just Income

AbbVie, Johnson & Johnson and Merck offer growing dividends alongside healthcare pipeline catalysts, regulatory approvals and rising analyst price targets heading into 2027.

MarketBeat · Sep 30

This Blue-Chip Dividend Stock Is Outperforming the S&P 500 in 2026

Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.

Barchart · Jul 9

Wall Street Says Buy Merck Over Pfizer. The Numbers Tell a More Complicated Story.

A tougher market puts two healthcare dividend giants in focus, as investors weigh income, stability, valuation, and long-term upside.

Barchart · Apr 24

Nasdaq Futures Climb on Blowout Palantir Results

March Nasdaq 100 E-Mini futures (NQH26) are trending up +0.41% this morning as forecast-beating quarterly results and guidance from Palantir Technologies boosted sentiment.

Barchart · Feb 3

2 Dividend Stocks to Buy Now for Big Payout Growth Ahead

Merck and Qualcomm combine strong cash flow with steady dividend growth, signaling potential for meaningful payout increases ahead.

Barchart · Nov 26, 2025

Are Wall Street Analysts Predicting Merck & Co. Stock Will Climb or Sink?

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart · Nov 3, 2025

Merck's New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Cancer

On Tuesday, Merck Co. Inc. (NYSE:MRK) and Eisai shared topline data from the Phase 3 LITESPARK-011 trial of the dual oral regimen of Welireg (belzutifan) plus Lenvima (lenvatinib).

Benzinga · Oct 28, 2025

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials

The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.

Benzinga · Oct 15, 2025